接受间隔16周剂量的BNT162b2 mRNA疫苗接种的个体血浆对SARS-CoV-2奥密克戎刺突蛋白的识别
SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses.
作者信息
Chatterjee Debashree, Tauzin Alexandra, Marchitto Lorie, Gong Shang Yu, Boutin Marianne, Bourassa Catherine, Beaudoin-Bussières Guillaume, Bo Yuxia, Ding Shilei, Laumaea Annemarie, Vézina Dani, Perreault Josée, Gokool Laurie, Morrisseau Chantal, Arlotto Pascale, Fournier Éric, Guilbault Aurélie, Delisle Benjamin, Levade Inès, Goyette Guillaume, Gendron-Lepage Gabrielle, Medjahed Halima, De Serres Gaston, Tremblay Cécile, Martel-Laferrière Valérie, Kaufmann Daniel E, Bazin Renée, Prévost Jérémie, Moreira Sandrine, Richard Jonathan, Côté Marceline, Finzi Andrés
机构信息
Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
出版信息
Cell Rep. 2022 Mar 1;38(9):110429. doi: 10.1016/j.celrep.2022.110429. Epub 2022 Feb 8.
Continuous emergence of SARS-CoV-2 variants of concern (VOCs) is fueling the COVID-19 pandemic. Omicron (B.1.1.529) rapidly spread worldwide. The large number of mutations in its Spike raise concerns about a major antigenic drift that could significantly decrease vaccine efficacy and infection-induced immunity. A long interval between BNT162b2 mRNA doses elicits antibodies that efficiently recognize Spikes from different VOCs. Here, we evaluate the recognition of Omicron Spike by plasma from a cohort of SARS-CoV-2 naive and previously infected individuals who received their BNT162b2 mRNA vaccine 16 weeks apart. Omicron Spike is recognized less efficiently than D614G, Alpha, Beta, Gamma, and Delta Spikes. We compare with plasma activity from participants receiving a short (4 weeks) interval regimen. Plasma from individuals of the long-interval cohort recognize and neutralize better the Omicron Spike compared with those who received a short interval. Whether this difference confers any clinical benefit against Omicron remains unknown.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变异株的持续出现推动了新冠疫情的发展。奥密克戎（B.1.1.529）在全球迅速传播。其刺突蛋白（Spike）上的大量突变引发了人们对主要抗原漂移的担忧，这可能会显著降低疫苗效力和感染诱导的免疫力。BNT162b2 mRNA疫苗两剂接种间隔时间延长可诱导出能有效识别不同变异株刺突蛋白的抗体。在此，我们评估了一组未感染过SARS-CoV-2以及既往感染过SARS-CoV-2且接种BNT162b2 mRNA疫苗间隔16周的个体血浆对奥密克戎刺突蛋白的识别情况。与D614G、阿尔法、贝塔、伽马和德尔塔刺突蛋白相比，奥密克戎刺突蛋白的被识别效率较低。我们将其与接受短间隔（4周）接种方案的参与者的血浆活性进行了比较。与接受短间隔接种的个体相比，长间隔组个体的血浆对奥密克戎刺突蛋白的识别和中和能力更强。这种差异是否能对奥密克戎产生任何临床益处尚不清楚。
Zotero 插件